Treatment of infection due to Pneumocystis carinii.
Fishman
J A
JA
Infectious Disease Unit, Massachusetts General Hosptial, Boston, Massachusetts 02114, USA. jfishman@helix.mgh.harvard.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D053626:Atovaquone; D002981:Clindamycin / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D000518:Eflornithine / Q000627:therapeutic use; D006801:Humans; D018942:Macrolides; D009285:Naphthoquinones / Q000627:therapeutic use; D010419:Pentamidine / Q000627:therapeutic use; D011010:Pneumocystis / Q000187:drug effects*; D016720:Pneumocystis Infections / Q000097:blood / Q000188:drug therapy; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D016597:Trimetrexate / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D018942:Macrolides; D009285:Naphthoquinones; D011743:Pyrimidines; D002981:Clindamycin; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; C024530:piritrexim; D016597:Trimetrexate; D053626:Atovaquone; D000518:Eflornithine